Skip to Content
Merck
All Photos(1)

Documents

B7431

Sigma-Aldrich

Bryostatin 1

≥99%, solid

Synonym(s):

NSC 339555

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C47H68O17
CAS Number:
83314-01-6
Molecular Weight:
905.03
MDL number:
MFCD00893832
UNSPSC Code:
12352200
PubChem Substance ID:
24891991
NACRES:
NA.77

Quality Level

100

Assay

≥99%

form

solid

color

white

solubility

DMSO: soluble
ethanol: soluble

storage temp.

−20°C

SMILES string

[H]\C(C(=O)OC)=C1/C[C@@]2([H])C[C@]3(O)O[C@]([H])(C[C@@H](O)CC(=O)O[C@H](C[C@]4([H])C\C(=C(\[H])C(=O)OC)[C@H](OC(=O)\C=C\C=C\CCC)[C@@](O)(O4)C(C)(C)\C=C\[C@@]([H])(C1)O2)[C@@H](C)O)C[C@H](OC(C)=O)C3(C)C

InChI

1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1

InChI key

MJQUEDHRCUIRLF-TVIXENOKSA-N

Application

Bryostatin 1 has been used to study its effects on spontaneous Crohn′s disease (CD) like colitis in mice. It has also been used to study its effects as an anthelmintic drug on adult Syphacia muris infection in rats.

Biochem/physiol Actions

Bryostatin 1 (Bry1) is a macrocyclic lactone. This synaptogenic compound is obtained from the marine bryozoan Bugula neritina. Bry1 is capable of reversing synaptic loss. It can enable synaptic maturation in animal models with several neurological disorders. It possesses antidepressant activity, when administered intracebroventricularly. Bry1 is known to participate in protecting cell tight junctions (TJs), anti-inflammatory functions and immune regulation.
Macrolactone isolated from the marine bryozoan Bugula neritina that initially activates and subsequently down-regulates protein kinase C (PKC). More potent than phorbol myristate acetate for translocating PKCδ and ε.

Other Notes

Binds to glass and plastic in aqueous solutions

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

N Kedei et al.
Biochemical pharmacology, 85(3), 313-324 (2012-11-14)
Bryostatin 1, like the phorbol esters, binds to and activates protein kinase C (PKC) but paradoxically antagonizes many but not all phorbol ester responses. Previously, we have compared patterns of biological response to bryostatin 1, phorbol ester, and the bryostatin
Dan Zhao et al.
Cellular immunology, 271(2), 392-400 (2011-09-10)
The majority of melanoma cells express detectable levels of HLA class II proteins, and an increased threshold of cell surface class II is crucial for the stimulation of CD4+ T cells. Bryostatin-1, a protein kinase C (PKC) activator, has been
Yasuyuki Ogawa et al.
The Journal of organic chemistry, 78(1), 104-115 (2012-11-06)
The Prins cyclization of syn-β-hydroxy allylsilanes and aldehydes gives cis-2,6-disubstituted 4-alkylidenetetrahydropyrans as sole products in excellent yields regardless of the aldehyde (R″) or syn-β-hydroxy allylsilane substituent (R') used. By reversing the R″ and R' groups, complementary exocyclic stereocontrol can be
Maria Eugenia Ariza et al.
The Journal of biological chemistry, 286(1), 24-34 (2010-11-03)
Bryostatin-1 (Bryo-1), a natural macrocyclic lactone, is clinically used as an anti-cancer agent. In this study, we demonstrate for the first time that Bryo-1 acts as a Toll-like receptor 4 (TLR4) ligand. Interestingly, activation of bone marrow-derived dendritic cells (in
B Douglas Smith et al.
Leukemia research, 35(1), 87-94 (2010-07-06)
Pharmacologic differentiating agents have had relatively limited clinical success outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase inhibitors in myelodysplastic syndromes. The differentiating effects of such agents can be enhanced in combination with lineage-specific growth
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service